Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Taysha Gene Therapies (NASDAQ: TSHA) Receives $50 Million Strategic Investment From Astellas Pharma to Develop AAV-Based Gene Therapeutics

Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is a biotechnology company that is focused on developing gene therapies to treat monogenic CNS disease. Shares of the gene therapy company are soaring 47% through early trading on Tuesday, October 25, 2022. Over the past three months, Taysha Gene Therapies has seen average daily volume of 112,820 shares. However, volume of 34.49 million shares or dollar volume of around $76.91 million, has already exchanged hands through early trading.

Shares of Taysha are surging after the company announced that it has received a strategic investment from Astrellas Pharma, Inc. to support to development of Taysha’s adeno-associated virus (AAV) gene therapy programs for the treatment of Rett syndrome and GAN.

Under the terms of the agreement, Astellas will invest a total of $50 million to acquire a 15% stake in Taysha. In exchange, Astrellas will receive the exclusive option to license two of Taysha’s drug candidate programs: TSHA-102 for the treatment of Rett syndrome and TSHA-120 for the treatment of GAN. Astrellas will also receive one board observer seat on the Taysha Board of Directors.

TSHA-102 is a first-and-only gene therapy that is currently undergoing clinical development for Rett syndrome. The TSHA-120 drug candidate is currently in Phase 1/2 clinical trial development for GAN and is awaiting regulatory feedback.

Astrellas has been working diligently to build out its gene therapy capabilities through its acquisition of Audentes in January 2020. The company has subsequently constructed a state-of-the-art GMP manufacturing facility in North Carolina, which officially opened in June of 2022.

“We are excited to enter this strategic investment with Astellas, a premier biopharmaceutical company with global R&D, manufacturing and commercial capabilities,” said RA Session II, Taysha’s Chief Executive Officer. “We believe this investment not only further validates the potential of our technology platform, but also reinforces the therapeutic and market opportunity of our two lead clinical assets.”

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post Taysha Gene Therapies (NASDAQ: TSHA) Receives $50 Million Strategic Investment From Astellas Pharma to Develop AAV-Based Gene Therapeutics appeared first on Spotlight Growth.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.